WHO welcomes FDA approval of new formulation of dolutegravir for young children living with HIV

WHO welcomes the recent decision by the U.S. Food and Drug Administration (FDA) to approve a dispersible 5 mg formulation of dolutegravir (DTG) for use in infants and children living with human immunodeficiency virus type 1 (HIV-1). The tablet, taken orally, has been approved for use in paediatric patients from four weeks of age weighing at least 3 kg in combination with other antiretroviral treatments.

source https://www.who.int/news-room/detail/18-06-2020-who-welcomes-fda-approval-of-new-formulation-of-dolutegravir-for-young-children-living-with-hiv